Escitalopram filed in Japan for depression
This article was originally published in Scrip
Lundbeck's licensee Mochida has filed an approval application in Japan for escitalopram for the treatment of depression, some eight years after it first gained the local rights to the selective serotonin reuptake inhibitor (SSRI).
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.